ITP Drug Shows Benefit in Hospitalized COVID Patients
(MedPage Today) -- BOSTON -- Fostamatinib (Tavalisse) added to standard care reduced the number of days on supplemental oxygen and improved clinical status in hospitalized patients with COVID-19, the phase III randomized FOCUS trial showed.
In...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news
More News: COVID-19 | Infectious Diseases